Neurology
Opicapone will be listed for the first time as additional therapy to treat Parkinson’s disease, helping other medications work better and for ...
February 02, 2023 | News
This annual international research prize of US$25,000 is awarded to young scientists for their outstanding contributions to neurobiological research based ...
February 02, 2023 | News
AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to address critical unmet medical needs in neurological, psyc...
January 17, 2023 | News
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mass...
January 16, 2023 | News
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and Drug...
January 09, 2023 | News
Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with ...
December 23, 2022 | News
STADA receives from BIAL exclusive rights to market and distribute Ongentys (opicapone) capsules in Australia STADA Specialty Head Bryan Kim: "Ongentys ...
December 19, 2022 | News
Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression ...
December 15, 2022 | News
Washington University is world leading in research on prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases. The two organizations ...
December 15, 2022 | News
£105 million to speed up diagnosis of rare genetic diseases in newborns, potentially resulting in life-saving interventions for thousands of babies...
December 15, 2022 | News
From reagent specialist to global player with a broad network of long-standing distribution partners in more than 160 countries • Covering a compre...
December 05, 2022 | News
Launches 'Sangobion Anaemia meter', a convenient online tool that empowers consumers to screen themselves for the risks of iron deficiency, the most c...
November 28, 2022 | News
Company aims to launch one new product or indication every 1.5 years on average, bolstered by external innovation Phase III assets xevinapant and evobru...
November 23, 2022 | News
TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation ...
November 22, 2022 | News
Most Read
Bio Jobs
News